Brand Name(s): Activase; TPA
CAS nš: 105857-23-6
(al-te-plase)
About Alteplase
This new site is dedicated exclusively to alteplase.
It provides you with the most extensive product information and up-to-date resources regarding this medication, including related news articles, medical studies, an image library and all the necessary information on dosage and side effects.
Whether you are an average consumer or a pharma industry professional, you can now find out everything you need to know about alteplase on this reference site, as well as take part in our open discussion forum by sharing your own knowledge and experience with people who are using this medication.
This unique site will also provide you with inside industry news on which companies or organizations are playing an important part in its research, development, production and promotion. It is your one-stop site for a total alteplase experience!
Why is this medication prescribed?
Alteplase is used to treat people who have suffered heart attacks (acute myocardial infarctions), strokes, chest pain at rest (unstable angina), blood clots in the lungs (pulmonary thrombosis or embolism), and other less common conditions involving blood clots.
Alteplase is an enzyme that occurs naturally in man and causes blood clots to dissolve. It is a man-made protein manufactured by recombinant DNA technology. The naturally occurring protein, known as tissue plasminogen activator (TPA), is made by ovarian cells from the Chinese hamster. Nevertheless, the amount that is given to patients is far greater than the amount naturally made by the body itself.
Latest News
Intraclot alteplase injection an option for treating lower extremity DVT
As an alternative to continuous-infusion thrombolytic regimens, direct intraclot injection of...
[more]Study Suggests Thrombolysis Therapy With Alteplase Could Be Used Routinely for Stroke Treatment
The thrombolytic drug alteplase, despite recent concerns, is safe and effective in routine clinical...
[more]Investors Dump Nuvelo On Alfimeprase's Phase III Data
Bad news for Nuvelo Inc.: Its partnered thrombolytic drug alfimeprase failed two Phase III studies,...
[more]Asymptomatic Hemorrhage After Thrombolysis May Not Be Benign. Prognosis by Hemorrhage Type in the Canadian Alteplase for Stroke Effectiveness Study Registry.
BACKGROUND AND PURPOSE: There is ongoing controversy about the impact of hemorrhagic transformation...
[more]Alteplase for the Treatment of Central Venous Catheter Occlusion in Children: Results of a Prospective, Open-label, Single-arm Study (The Cathflo Activase Pediatric Study).
PURPOSE: Alteplase is approved for use in the restoration of function to occluded central venous...
[more]